Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited has reported a robust 16% increase in annual profit after tax, reaching $35.6 million for FY2024, backed by a significant rise in product demand and effective cost management. The company’s revenue surged by 15% to $95.3 million, while maintaining a stable dividend distribution, underscoring its sustained profitability and shareholder value. Clinuvel’s financial strength is further highlighted by the growth of cash reserves to $183.9 million, ensuring the company’s ability to self-finance and mitigate economic risks.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
